Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emcure Aims To Split Itself In Half

Seeking Private-Equity Investment

Executive Summary

By the middle of next year, Emcure intends to have demerged its operations in highly developed markets from its activities in India and other emerging markets. The Indian group is seeking private-equity support to grow inorganically in North America and Europe.

You may also be interested in...



Two India Firms In Fresh FDA Trouble: Emcure Hit By Warning Letter, Dr Reddy’s Gets 483

The US regulator has slammed India’s Emcure Pharmaceuticals in a warning letter, accusing the company of slipshod investigation of tests showing microbial contamination and poor supervision, and has also sent a Form 483 containing eight observations to Dr Reddy’s.

Heritage Clarifies No Guilty Plea In US Settlement

Heritage has clarified that its recent settlement deal with the US Department of Justice over price-fixing allegations did not include the company entering a guilty plea.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel